UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April 18~~May 15, 2025

FORTE BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-38052

26-1243872

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3060 Pegasus Park Dr.

Building 6

Dallas, Texas

75247

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (310) 618-6994

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradingSymbol~~Trading Symbol(s)		Name of each ~~exchangeon~~exchange on which registered
Common Stock, $0.001 par value		FBRX		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 82.0102. Results ~~Other~~of ~~Events~~Operations and Financial Condition.

On ~~April~~May 1815, 2025, ~~the Board of Directors of~~ Forte Biosciences, Inc., issued a ~~Delaware~~press ~~corporation~~release ~~(the~~reporting ~~“Company”)~~its ~~determined~~financial toresults ~~hold~~for the ~~Company’s~~quarter ~~annual~~ended ~~meeting of stockholders (the “Annual Meeting”) on May~~March 2931, 2025. ~~The~~A ~~time~~copy ~~and location~~ of the ~~Annual~~press ~~Meeting~~release ~~will~~is befurnished herewith as ~~set~~Exhibit ~~forth~~99.1 ~~in the Company’s proxy materials~~ to bethis ~~filed~~Current ~~with~~Report ~~the~~on ~~Securities~~Form ~~and Exchange Commission~~8-K.

~~Because~~The ~~the~~information ~~scheduled~~furnished ~~date of the Annual Meeting is more than 30 days before the anniversary date of the Company’s 2024 annual meeting of stockholders, prior deadlines regarding the submission of stockholder proposals~~ in ~~connection~~this ~~with~~Current ~~the~~Report ~~Annual~~under ~~Meeting~~Item ~~are no longer applicable~~2.02 ~~The~~and ~~Company is hereby providing notice of certain revised deadlines for~~ the ~~submission~~exhibit ofattached ~~stockholder~~hereto ~~proposals~~shall innot ~~connection with the Annual Meeting. In order for a stockholder proposal, submitted pursuant to Rule 14a-8, to~~ be ~~considered~~deemed ~~timely~~“filed” for ~~inclusion~~purposes ~~in the Company’s proxy statement and form~~ of ~~proxy for the Annual Meeting, such proposal must be received by the Company by April~~Section ~~28,~~18 ~~2025.~~of ~~The Company has determined that April 28, 2025 is a reasonable time before~~ the ~~Company~~Securities ~~plans~~Exchange toAct ~~begin~~of ~~printing and mailing its proxy materials. Therefore~~1934, inas ~~order~~amended ~~for a stockholder to submit a proposal for inclusion in~~ (the ~~Company’s~~“Exchange ~~proxy materials for the Annual Meeting~~Act”), ~~the~~or ~~stockholder~~incorporated ~~must~~by ~~comply~~reference ~~with the requirements set forth~~ in ~~Rule~~any ~~14a-8,~~filing ~~including~~under ~~with respect to~~ the ~~subject~~Securities ~~matter~~Act of ~~the proposal~~1933, ~~and~~as ~~must deliver the proposal and all required documentation to the Company no later than April 28~~amended, ~~2025. The public announcement of an adjournment~~ or ~~postponement of~~ the ~~date~~Exchange ofAct, ~~the~~except ~~Annual~~as ~~Meeting~~shall ~~will~~be ~~not~~expressly ~~commence~~set aforth ~~new~~by ~~time~~specific ~~period~~reference ~~(or~~in ~~extend~~such ~~any time period) for submitting~~ a ~~proposal pursuant to Rule 14a-8~~filing.

Generally, timely notice of any director nomination or other proposal that any stockholder intends to present at the Annual Meeting, but does not seek to have included in the proxy materials pursuant to Rule 14a-8, must be delivered no later the 10th day following the day on which public announcement of the date of the Annual Meeting is first madeItem 9.01. ~~Therefore,~~Financial inStatements ~~order~~and for a stockholder to timely submit a director nomination or other proposal that the stockholder intends to present at the Annual Meeting, the stockholder must deliver the director nomination or proposal to the Company no later than April 28, 2025Exhibits.

In(d) ~~addition,~~Exhibits to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by April 28, 2025, which is 10 days following the filing of this Current Report on Form 8-K announcing the date of the Annual Meeting.


Exhibit		Description

99.1		Press Release dated May 15, 2025.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FORTE BIOSCIENCES, INC.

Date: April 18, 2025

/s/ Antony Riley

Date: May 15, 2025

/s/ Antony Riley

Antony Riley Chief Financial Officer

Filing Compare · Forte Biosciences, Inc.